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ABSTRACT
Objective: To examine retrospectively the effects of plasmapheresis (PLEX) on the survival and
clinical outcomes of patients with multiple sclerosis (MS) and natalizumab (NTZ)–associated
progressive multifocal leukoencephalopathy (PML).
Methods: The medical literature was searched for the terms natalizumab and progressive multi-
focal leukoencephalopathy. A total of 193 international and 34 Italian NTZ-PML cases were
included. Clinical outcome was determined by comparing the patients’ clinical status at PML
diagnosis with status after PML resolution. The effects on survival and clinical outcome of PLEX,
sex, age, country, pre-PML Expanded Disability Status Scale score, NTZ infusion number, prior
immunosuppressant exposure, PML symptoms, PML lesion location at diagnosis, CSF JC virus
status and copies, additional PML treatments and steroids, and PML immune reconstitution
inflammatory syndrome (IRIS) development were investigated with both univariate and multivar-
iate analyses.
Results: A total of 219 NTZ-PML cases were analyzed, and 184 (84%) underwent PLEX, which did
not reduce the mortality risk or the likelihood of poor vs favorable outcomes. Country was predictive
of mortality and poor outcome, while PML-IRIS development was predictive of poor outcome.
Conclusions: PLEX did not improve the survival or clinical outcomes of Italian or international pa-
tients with MS and NTZ-PML, suggesting that this treatment should be performed cautiously in
the future.
Classification of evidence: This study provides Class III evidence that for patients with NTZ-PML,
PLEX does not improve survival. The study lacks the statistical precision to exclude an important
benefit or harm of PLEX. Neurology® 2017;88:1144–1152
GLOSSARY
EDSS5 Expanded Disability Status Scale; HR5 hazard ratio; IRIS5 immune reconstitution inflammatory syndrome; JCV 5
JC virus; MS 5 multiple sclerosis; NTZ 5 natalizumab; PLEX 5 plasmapheresis; PML 5 progressive multifocal leukoence-
phalopathy; ROW 5 rest of the world.
Natalizumab (NTZ) treatment in patients with multiple sclerosis (MS) is associated with an
increased risk of the development of progressive multifocal leukoencephalopathy (PML), an
opportunistic infection caused by the JC virus (JCV). As of March 4, 2016, 635 cases of
NTZ-associated PML (NTZ-PML) have been confirmed in patients with MS in the postmar-
keting setting (hcp.biogen-international.com/tysabri_update.aspx?ID522076). No specific
treatments are available, and the NTZ-PML mortality rate is about 24% (hcp.biogen-
international.com/tysabri_update.aspx?ID522076).1 Older age, high pre-PML disability, high
number of CSF JCV copies, MRI findings consistent with multifocal damage, and worse
Karnofsky Performance Scale scores at the time of PML diagnosis are predictive of poor
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outcome.1 To limit infection in the brain, the
rapid restoration of immunosurveillance is
encouraged by interrupting the treatment
and accelerating the removal of plasma
NTZ, which is biologically active for up to 3
months after its infusion, with plasmapheresis
(PLEX), which exchanges the plasma with
donor plasma or albumin. Although the effec-
tiveness of PLEX and the optimum treatment
regimen have never been systematically inves-
tigated, PLEX is usually highly recommended
in the management of NTZ-PML.2,3
Although effective in removing NTZ, PLEX
might be detrimental for patient outcome,
increasing the likelihood of the development
of immune reconstitution inflammatory
syndrome (IRIS) and of inflammatory brain
damage4 from the rapid restoration of
immunosurveillance.
In this study, we retrospectively analyzed
193 international NTZ-PML cases reported
in the literature and 34 Italian NTZ-PML
cases with the aim of estimating the risk/ben-
efit profile of PLEX in NTZ-PML.
METHODS PubMed search. We searched PubMed for
English articles that were published from January 2005 to June
2015 and that included the terms natalizumab and progressive
multifocal leukoencephalopathy. We found 487 articles. Subse-
quently, we selected only those articles that reported clinical de-
scriptions of the NTZ-PML patients, regardless of the original
aim of the study. Articles lacking meaningful clinical
information about the patients’ PML diagnosis, treatments, and
outcome, as well as articles about patients without MS (e.g.,
Crohn disease) who were treated with NTZ, were excluded.
Patients described by multiple articles were listed once in the
database with the most informative article listed as the source
document. We excluded the following: cases and clinical series
with suspected overlap between articles, previously published,
Italian patients who were already included in the Italian
dataset, and case series from which individual clinical
information could not be extracted.
International published cases. A final sample of 193 interna-
tional NTZ-PML cases, collected from 49 articles,e1–e44,5–9 was
included in this study. All of the cases fulfilled the PML
diagnostic criteria suggested by Berger et al.10
For each case, we extracted the following demographic and
clinical information: sex (male/female), age at time of PML diag-
nosis (years), country (Europe, United States, or rest of the world
[ROW]), Expanded Disability Status Scale (EDSS) score prior to
PML diagnosis, prior immunosuppressant exposure (yes/no),
number of NTZ infusions at time of PML diagnosis, presence
of symptoms at PML diagnosis (yes/no), PML lesion localization
at diagnosis (supratentorial/infratentorial/both), CSF-JCV status
at diagnosis (positive/negative), number of CSF-JCV copies (any-
time; i.e., first CSF-JCV-positive PCR), PLEX treatment (yes/
no), additional treatments (mefloquine, mirtazapine, both, none),
PML-IRIS development (yes/no), interval between PML
Table 1 Descriptive characteristics of the population
PLEX1 (n 5 184) PLEX2 (n 5 35) p Value
Sex, n (%) 0.02a
Male 61 (33) 4 (11)
Female 123 (67) 31 (89)
Age at PML diagnosis, y, mean (6SD)b 43.3 (68.9) 40.9 (610.7) 0.26
Country, n (%) 0.36
Europe 136 (74) 29 (83)
US and ROW 48 (26) 6 (17)
Pre-PML EDSS, median (range)c 3.5 (0–7.5) 3.5 (1.0–7.0) 0.64
No. of NTZ infusions, mean (6SD)d 31.9 (612.7) 35.9 (614.8) 0.10
Prior immunosuppressants, n (%) 0.09
Yes 38 (36) 5 (17)
No 68 (64) 24 (83)
EDSS at PML diagnosis,
median (range)e
5.0 (0–9.0) 4.0 (2.0–8.0) 0.62
Symptoms at PML diagnosis, n (%) 0.60
Yes 95 (92) 27 (87)
No 8 (8) 4 (13)
PML lesion localization at
diagnosis, n (%)
0.04a
Supratentorial 69 (87) 17 (68)
Infratentorial 6 (7) 2 (8)
Both 5 (6) 6 (24)
CSF JCV status at diagnosis, n (%) 0.25
Positive 160 (88) 27 (79)
Negative 21 (12) 7 (21)
CSF JCV copies/mL (anytime),
median (interval)f
340 (0–4,831,575) 57 (0–26,300) 0.001a
Additional treatments, n (%) 0.002a
None 35 (38) 23 (72)
Mefloquine or mirtazapine 56 (62) 9 (18)
PML-IRIS development, n (%) 0.99
Yes 92 (81) 24 (83)
No 21 (19) 5 (17)
PML diagnosis–IRIS interval, d,
median (interval)g
27.5 (0–90) 45 (6–120) 0.14
Treatment with steroids, n (%) 0.99
Yes 72 (80) 26 (81)
No 18 (20) 6 (19)
EDSS at last available follow-up,
median (interval)h
7.5 (0–10) 6.0 (1.5–10) 0.16
Final outcome, n (%) 93 25 0.48
Improved 19 (21) 7 (28)
Stable 15 (16) 4 (16)
Worsened 30 (32) 10 (40)
Death 29 (31) 4 (16)
Continued
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diagnosis and IRIS development (days), use of steroids for the
treatment/prevention of IRIS (yes/no), clinical status at last exam-
ination available after PML resolution, and post-PML follow-up
(months). PML-IRIS development and clinical status after PML
were defined according to the authors’ statements.
Italian cases. Thirty-four Italian NTZ-PML patients were
included in this study. The data were retrospectively collected
by Dr. Capra and collaborators from 25 Italian MS centers that
were allowed to prescribe NTZ in accordance with the
regulations of the Italian authorities. The majority (n 5 20) of
the centers reported only 1 NTZ-PML patient, and only 1 site
reported 4 NTZ-PML patients. In order to confirm the NTZ-
PML diagnoses, the clinical and radiologic data sent by each
center were reanalyzed. The same diagnostic criteria for NTZ-
PML as those cited above were applied. For the Italian cases, the
same clinical variables as those described for the international
cases were collected.
Standard protocol approvals, registrations, and patient
consents. International published cases. Because we analyzed
data that were obtained from published reports, neither ethics
committee approval nor informed consent was required.
Italian cases. The ethics committee of the Spedali Civili of
Brescia approved the retrospective analysis of the patient data.
Outcome variables. For the primary outcome measures, we
examined survival and post-PML clinical status. Nonsurvivors were
patients who died at any time due to PML complications after
being diagnosed with PML (e.g., 1 Italian patient died because of
cholecystitis that was unrelated to the PML, and, therefore, he was
considered a survivor). The post-PML clinical status was compared
to the PML clinical status at the diagnosis and rated as stable,
improved, worsened, or dead based on the reported clinical
descriptions, EDSS/Karnofsky Performance Scale scores, or authors’
statements. The post-PML neurologic evaluation that was last
available at the time of the writing of each article was used. Any
stated change in disability was considered a clinical impairment/
worsening, regardless of the magnitude of the effect.
The median interval of follow-up (months) between PML diag-
nosis and the last available evaluation or outcome reached (e.g.,
death), whichever came first, is specified in table 1. For the Italian
cohort, the PML clinical outcome was assessed at 12 months.
Statistical analysis. The descriptive statistics are expressed as
count (percentage) for discrete variables and mean (SD) or
median (range) for continuous variables. The cohort was divided
into 2 groups (PLEX1 and PLEX2) according to PLEX admin-
istration. The differences between the patients who underwent
PLEX and those who did not were explored with x2 tests or
Mann-Whitney U tests for categorical or continuous variables,
respectively. Patients who were administered immunoadsorption
were included in the PLEX1 group.
To assess the effects of PLEX and the demographic, clini-
cal, and treatment variables on outcome after PML, univariate
and multivariate Cox proportional hazards models were con-
structed with the 2 different outcomes, namely, overall mortal-
ity and the 4 ratings defining the patients after PML as
improved or stable vs worsened or dead, considered the depen-
dent variables. The demographic and clinical covariates that
were associated with the aforementioned clinical outcomes
with p values #0.10 in the univariate analysis were included
in the multivariate models that included PLEX as the indepen-
dent variable of interest. The multivariate models were cor-
rected for sex and age.
Because the main objective of the present study was to analyze
the association between PLEX treatment and outcome, PLEX
was included in the multivariate models even if it was not statis-
tically significant in the univariate analyses. The number of CSF-
JCV copies was log-transformed due to its positively skewed
distribution.
The primary research question was to evaluate whether PLEX
improves survival and clinical outcomes in patients with NTZ-
PML.
Level of evidence. This study provides Class III evidence that
for patients with NTZ-PML, PLEX does not improve survival.
Table 1 Continued
PLEX1 (n 5 184) PLEX2 (n 5 35) p Value
Death, n (%) 0.66
Yes 29 (16) 4 (11)
No 152 (84) 31 (89)
Follow-up time, mo, median (interval)i 11 (,1–35) 12 (,1–26) 0.20
Abbreviations: EDSS 5 Expanded Disability Status Scale; IRIS 5 immune reconstitution
inflammatory syndrome; JCV 5 JC virus; NTZ 5 natalizumab; PLEX 5 plasmapheresis;
PML 5 progressive multifocal leukoencephalopathy; ROW 5 rest of the world.
The percentages were estimated from the number of available observations.
a Significant.
b The number of available observations for PLEX1/PLEX2: 182/35.
c The number of available observations for PLEX1/PLEX2: 54/20.
d The number of available observations for PLEX1/PLEX2: 183/34.
e The number of available observations for PLEX1/PLEX2: 40/16.
f The number of available observations for PLEX1/PLEX2: 168/30.
g The number of available observations for PLEX1/PLEX2: 52/6.
h The number of available observations for PLEX1/PLEX2: 66/20.
i The number of available observations for PLEX1/PLEX2: 72/25.
Figure 1 Clinical severity of natalizumab–progressive multifocal leukoence-
phalopathy (PML) at diagnosis
Clinical severity of PML (estimated as number of signs/symptoms) at diagnosis. PLEX 5
plasmapheresis.
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Table 2 Univariate and multivariate Cox hazard model analyses (using months of follow-up as the time
variable) assessing the effects of plasmapheresis (PLEX) and the demographic and clinical
variables on mortality after progressive multifocal leukoencephalopathy (PML) (events included in
the analysis 5 9)
Variables No.
Univariate analysis Multivariate analysis
HR 95% CI p Value HR 95% CI p Value
PLEX
No 25 1.00 — — 1.00 — —
Yes 72 1.25 0.40–3.92 0.70 0.30 0.06–2.70 0.14
Sex
Female 75 1.00 — —
Male 22 1.90 0.65–5.58 0.24
Age at PML diagnosis
Each year 97 1.04 0.98–1.10 0.20
Country
Europe 80 1.00 — — 1.00 — —
US 1 ROW 17 21.25 6.95–64.96 ,0.001a 5.78 0.97–34.36 0.05a
Pre-PML EDSS
Each step 72 0.86 0.56–1.31 0.47
No. of NTZ infusions
Each unit 95 0.99 0.95–1.03 0.57
Prior immunosuppressants
No 60 1.00 — —
Yes 24 0.95 0.29–3.06 0.93
EDSS at PML diagnosis
Each step 56 0.94 0.61–1.46 0.80
Asymptomatic PML
No 11 1.00 — —
Yes 81 0.04 0.01–43.29 0.37
PML lesion localization
at diagnosis
Supratentorial 67 1.00 — —
Infratentorial 7 1.00 0.99–1.01 0.99
Both 9 2.01 0.41–9.82 0.39
CSF JCV status
Negative 15 1.00 — —
Positive 80 0.66 0.18–2.37 0.53
CSF JCV copies
Each log increase 86 1.74 1.12–2.73 0.01a 1.29 0.06–2.70 0.49
Additional treatments
No 43 1.00 — —
Yes 46 1.16 0.72–1.87 0.53
Time from PML diagnosis
to IRIS
Each day 36 0.98 0.95–1.02 0.33
PML-IRIS development
No 20 1.00 — —
Yes 72 29.70 0.10–1.03 3 104 0.26
Continued
Neurology 88 March 21, 2017 1147
ª 2017 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
The study lacks the statistical precision to exclude an important
benefit or harm of PLEX.
RESULTS After pooling the international and Italian
cases, we analyzed the data for 227 NTZ-PML
patients (56 from the United States and ROW, 137
from Europe, and 34 from the Italian cohort).
Eight patients were excluded from the final analysis
because the PLEX data were missing, which
resulted in a final sample of 219 patients. The
demographic and clinical characteristics of the
patients are summarized in table 1. All of
the patients stopped the NTZ treatment
immediately following the PML diagnosis. PLEX
was performed in 184 (84%) of the 219 patients.
The median number of PLEX courses (based on the
available data for 30 patients) was 5, with a range of 1
to 20 (5 courses repeated 4 times every 6 months).
The 2 groups (PLEX1 and PLEX2) significantly
differed for sex (p 5 0.02), CSF-JCV copies (p 5
0.001), use of additional treatments (p 5 0.002),
and PML lesion localization (p 5 0.04), as shown in
table 1. The clinical severity of the PML at diagnosis
did not differ between the PLEX1 and PLEX2 groups
(p 5 0.22; see figure 1). There was no between-group
difference for the follow-up intervals from the time of
PML diagnosis (p 5 0.20) (table 1).
The univariate analysis showed that mortality
(hazard ratio [HR] 1.25; confidence interval 0.40–
3.92; p 5 0.7; table 2) and the likelihood of improv-
ing or remaining stable compared to worsening or
dying (HR 1.25; p 5 0.47; table 3) did not differ
between the patients who were treated with PLEX
and those who were not. In addition, Kaplan-Meier
survival curves for overall survival and time to out-
come did not differ between the 2 groups (p . 0.4
with the log-rank test; figure 2). Country (United
States/ROW vs Europe) was a risk factor for both
mortality (HR 21.25; p , 0.001, table 2) and poor
outcome (HR 5.70; p , 0.001, table 3). The devel-
opment of PML-IRIS was also associated with an
increased risk of poor outcome (HR 6.35; p 5
0.01, table 3) but not with mortality. The number
of CSF-JCV copies was associated with a higher risk
of mortality (HR 1.74; p5 0.01, table 2). Moreover,
the univariate Cox hazard model analysis showed that
the treatment of PML-IRIS with steroids was a signif-
icant contributor to reduced mortality (HR 0.25; p5
0.04, table 2).
The multivariate Cox hazard model analysis of
mortality after PML found that country was the only
predictive variable (HR 5.78; p 5 0.05, table 2).
Country (HR 3.87; p 5 0.001, table 3) and PML-
IRIS development (HR 4.61; p5 0.04, table 3) were
also predictive of poor outcome in the multivariate
model.
DISCUSSION In recent years, PML has gained re-
newed attention due to reports of patients with MS
who were treated with the monoclonal antibody
NTZ. Because effective treatments for PML are not
available, the rapid reconstitution of immune surveil-
lance in the CNS through PLEX has been widely
encouraged in order to limit viral spread.2,3 Adher-
ence to this recommendation has been high world-
wide, as was demonstrated by the population data
gathered in this study. About 84% (184 of 219 cases)
of the entire NTZ-PML cohort had been treated with
PLEX, while only 16% had not. The reasons why
PLEX was not administered differed in each
instance (e.g., long interval between PML diagnosis
and NTZ withdrawal not requiring NTZ removal,8
first occurrences as adverse events in clinical trials,5,6
and lesion localization in eloquent areas, making the
risk of PML-IRIS unjustifiable11). This imbalance in
treatment approach confirmed that PLEX was
considered the treatment of choice for NTZ-PML
in clinical practice, even if clinical trials supporting
its efficacy in this population are lacking.
To fill this gap, we compared the clinical out-
comes of patients with MS and NTZ-PML who were
treated with PLEX with those who were not in the
present study. We did not find improvement in mor-
tality or residual disability in patients treated with
PLEX compared to the untreated patients. These
findings suggested that the spontaneous recovery of
immunocompetence after NTZ withdrawal might
counteract the spread of PML in patients with MS
Table 2 Continued
Variables No.
Univariate analysis Multivariate analysis
HR 95% CI p Value HR 95% CI p Value
PML-IRIS treatment with steroids
No 16 1.00 — — 1.00 — —
Yes 73 0.25 0.07–0.91 0.04a 0.28 0.05–1.67 0.16
Abbreviations: CI 5 confidence interval; EDSS 5 Expanded Disability Status Scale; HR 5 hazard ratio; IRIS 5 immune
reconstitution inflammatory syndrome; JCV 5 JC virus; NTZ 5 natalizumab; ROW 5 rest of the world.
aSignificant.
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Table 3 Univariate and multivariate Cox hazard model analysis (using months of follow-up as the time
variable) assessing the effects of plasmapheresis (PLEX) and the demographic and clinical variables
on the likelihood of poor vs favorable outcomes (i.e., worsened/dead vs improved/stable)
Variable No.
Univariate analysis Multivariate analysis
HR 95% CI p Value HR 95% CI p Value
PLEX
No 22 1.00 — — 1.00 — —
Yes 44 1.25 0.68–2.32 0.47 1.00 0.48–2.08 0.99
Sex
Female 70 1.00 — —
Male 20 1.49 0.77–2.87 0.23
Age at PML diagnosis
Each year 90 1.02 0.99–1.06 0.17
Country
Europe 73 1.00 — — 1.00 — —
US 1 ROW 17 5.70 2.98–10.93 ,0.001a 3.87 1.78–8.42 0.001a
Pre-PML EDSS
Each step 70 0.93 0.78–1.11 0.45
No. of NTZ infusions
Each unit 88 0.99 0.98–1.02 0.68
Prior immunosuppressants
No 57 1.00 — —
Yes 24 0.69 0.35–1.36 0.28
EDSS at PML diagnosis
Each step 56 0.96 0.81–1.14 0.68
Asymptomatic PML
No 11 1.00 — —
Yes 78 0.86 0.36–2.03 0.73
PML lesion localization
at diagnosis
Supratentorial 64 1.00 — —
Infratentorial 5 1.26 0.38–4.11 0.70
Both 9 1.11 0.43–2.87 0.82
CSF JCV status
Negative 14 1.00 — —
Positive 74 0.67 0.32–1.37 0.27
CSF JCV copies
Each log-increase 79 1.24 0.95–1.61 0.10 1.10 0.82–1.45 0.53
Additional treatments
No 37 1.00 — —
Yes 45 1.05 0.58–1.92 0.87
PML-IRIS development
No 19 1.00 — — 4.61 1.10–19.39 0.04a
Yes 66 6.35 1.54–26.25 0.01a
Treatment with steroids
No 16 1.00 — —
Continued
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and therefore not require any additional intervention.
Nevertheless, forcing the rapid restoration of immune
surveillance in the brain with PLEX may eventually
expose patients to an increased risk of aggressive
PML-IRIS.7 In PML, the primary infection occurs
in oligodendrocytes, which leads to oligodendrocyte
death and demyelination. PML-IRIS develops when
a massive amount of immunocompetent cells enter
the CNS and localize within and at the border of
visible PML lesions, where many infected oligoden-
drocytes are in a preapoptotic phase. These cells are
the target of T-cell-mediated cytotoxicity that is eli-
cited by immunoreconstitution and results in damage
to surrounding tissues and clinical worsening. In
addition, inflammation activates effector macro-
phages and microglia, further amplifying the inflam-
matory reaction and prompting blood–brain barrier
damage, brain injury, and cerebral edema.9 This
immunopathologic cascade is responsible for the
devastating effects that lead to great clinical disability
and possibly death.
In the present study, we confirmed the negative
prognosis of PML-IRIS. It is now widely accepted
that the more limited the infection and earlier the
diagnosis, the milder the PML-IRIS and the better
the postinfectious neurologic status.12 In our cohort,
we identified 13 asymptomatic patients, and 8 of 12
were treated with PLEX, while 4 were not (informa-
tion was missing for 1 patient). In this group, 5 of the
treated patients remained asymptomatic, while 3
worsened, and all of the untreated (4 of 4) patients
worsened. No one died. Therefore, even if the overall
analysis of our cohort had shown no positive effects of
PLEX on patient outcome, and the small number of
asymptomatic patients did not allow for a definitive
conclusion, we cannot rule out the hypothesis that
the benefits of PLEX may outweigh the risks in a sub-
group of patients in which the immune restoration
induced by PLEX is protective and not destructive.
Conversely, a slower recovery of immunocompetence
following NTZ withdrawal might be a more promis-
ing strategy in patients with widespread infection at
the time of diagnosis, while considering the increased
risks associated with PLEX in advanced cases13 and
the long interval between oligodendrocyte infection
and lysis.
In accordance with the findings of Dong-Si
et al.,1 we found that older age and country of ori-
gin, namely the United States and ROW, were
independently associated with poor outcome and
survival. Because PLEX is equally available and
applied across countries, other factors that were
Table 3 Continued
Variable No.
Univariate analysis Multivariate analysis
HR 95% CI p Value HR 95% CI p Value
Yes 66 0.65 0.32–1.35 0.25
Abbreviations: CI 5 confidence interval; EDSS 5 Expanded Disability Status Scale; HR 5 hazard ratio; IRIS 5 immune
reconstitution inflammatory syndrome; JCV 5 JC virus; NTZ 5 natalizumab; PML 5 progressive multifocal leukoencephal-
opathy; ROW 5 rest of the world.
aSignificant.
Figure 2 Natalizumab–progressive multifocal leukoencephalopathy (PML) outcomes
Kaplan-Meier curves show time to outcome (worsening or death, A) and overall survival (B) after PML diagnosis. PLEX 5
plasmapheresis.
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not evaluated in this study (e.g., time to diagnosis)
might explain these results.
The current study had several limitations. The
main limitations were related to the retrospective
structure of the analysis and the indirect collection
of the clinical measures derived from the published
cases. Moreover, because the datasets were created
by gathering information from studies that did
not have the same aim as that of the present study,
the data were often incomplete (i.e., data about
PLEX regimen, type of PLEX, interval between
NTZ withdrawal and PML diagnosis or PLEX
administration, time to death, magnetic resonance
lesion volume or specific lesion location descrip-
tion, and neurologic status at PML-IRIS develop-
ment). In our cohort, due to the limited
information available, we quantified PML-IRIS as
a dichotomous variable (PML-IRIS: yes/no).
Therefore, we could not estimate whether PML-
IRIS was more severe in patients who were treated
with PLEX, which should be addressed in future
studies. In addition, the need to extract meaningful
clinical information led us to exclude many articles
from the analysis, thus creating a potential selection
bias.
Notwithstanding these limitations, our study
failed to show an effect of PLEX on improving clinical
outcome and survival in Italian and international pa-
tients with MS who were diagnosed with NTZ-PML.
Considering the potential risks and costs of PLEX,
these results argue for caution and for individualized
decision-making regarding PLEX. The clinical rele-
vance of this problem justifies the performance of
prospective clinical studies in order to identify the pa-
tients who will more likely benefit from PLEX in
NTZ-PML treatment.
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